Topical lidocaine gel relieves postherpetic neuralgia
Postherpetic neuralgia (PHN) following herpes zoster is a common and disabling neuropathic pain syndrome, mainly affecting elderly patients. It has been under-diagnosed and under-treated and such patients are at high risk of drug-drug interactions. Therefore, it is need of hour to establish efficacious and safe treatment with a low interaction potential.
This review focuses on this clinical safety and tolerability profile of the 5% lidocaine medicated plaster. The purpose of the present investigation was to study the clinical practice patterns of 5% lidocaine medicated plaster in treating neuropathic pain, for which 5% lidocaine-medicated plaster represents a new alternative with benefits outweighing risks.
A PubMed literature search was conducted up to June 26, 2014 to gather studies reporting the occurrence of adverse events and other safety issues regarding the use of 5% lidocaine medicated plaster for PHN and even unpublished clinical safety data were perused for this review. The 5% lidocaine medicated plaster demonstrated good short and long-term tolerability with a minimal risk for systemic adverse drug reactions.
This study adds to a growing body of evidence that 5% lidocaine medicated plaster can be considered a valuable treatment option for patients with PHN. In patients with PHN, lidocaine patch 5% has demonstrated pain relief with a minimal risk of systemic adverse effects or drug-drug interactions. Because of its proven efficacy and safety profile, lidocaine patch 5% has been recommended as a first-line therapy for neuropathic pain of PHN and as an alternative for patients unable to tolerate pregabalin. It was found in the study that plaster medicated with 5% lidocaine improves the quality of life with good safety profile, tolerability and effectiveness.